Gelmetix 3rd in prestigious EIT Health Catapult competition

Gelmetix won 3rd place in the final of the biotech category of the prestigious EIT Health Catapult competition

08 December 2020

We’re delighted to announce that  on 3rd December, with total prize winnings of €210,000 available among the best performers. The seven finalists represented best-in-class innovations in biotech across Europe, having been selected from hundreds of entrants.
EIT Health Catapult is a unique competition and training programme that showcases biotech, medtech and digital health start-ups to leading experts and investors across Europe. The programme recognises and awards the very best business concepts, fast-tracking start-ups to become part of the EIT Health Community of world-leading companies. EIT Health is supported by the European Institute of Innovation & Technology (EIT), a body of the European Union.
This fantastic achievement is a huge accolade affirming Gelmetix’s DXM product as a game-changer in disc nucleus augmentation and revolutionising treatment for chronic back pain.

For all press and media enquiries please email us at